Medicinal chemistry of the A3 adenosine receptor: Agonists, antagonists, and receptor engineering

Handbook of Experimental Pharmacology

Volumn 193, Issue , 2009, Pages 123-159

  Jacobson, Kenneth A ^a   Klutz, Athena M ^a   Tosh, Dilip K ^a   Ivanov, Andrei A ^a   Preti, Delia ^b   Baraldi, Pier Giovanni ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

A3 adenosine receptor; A3 adenosine receptor agonist; A3 adenosine receptor antagonist; G protein coupled receptor; Neoceptor; Nucleoside; Purines; Structure activity relationship

Indexed keywords

2 CHLORO N (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENINE; ADENINE DERIVATIVE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; FUNCTIONAL GROUP; HETEROCYCLIC COMPOUND; ISOQUINOLINE; NUCLEOSIDE; NUCLEOSIDE DERIVATIVE; OT 7999; PURINE DERIVATIVE; PYRAZOLOQUINOLINE DERIVATIVE; PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVE; QUINOZALINE DERIVATIVE; RIBOSE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLO[4,3 A]QUINOXALINE DERIVATIVE; TRIAZOLOPURINE DERIVATIVE; TRIAZOLOQUINOXALINE DERIVATIVE; TRICYCLIC XANTHINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ARTHRITIS; BINDING AFFINITY; CANCER CELL; CHO CELL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GLAUCOMA; HUMAN; HYDROGEN BOND; INFLAMMATION; LIGAND BINDING; MOLECULAR MODEL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349337301     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-89615-9_5     Document Type: Review

References (105)

1. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P (2005) Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 32:469-476
2. Baraldi PG, Cacciari B, Pineda de las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park K-S, Ji X-d, Jacobson KA (1998) Synthesis and biological activity of a new series of N6-arylcarbamoyl2-(ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido- derivatives of adenosine-5--N-ethyluronamide (NECA) as A1 and A3 adenosine receptor agonists. J Med Chem 41:3174-3185
3. Baraldi PG, Cacciari B, Borea PA, Varani K, Pastorin G, Da Ros T, Spalluto G (2002a) Pyrazolotriazolo- pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Curr Pharm Design 8:99-110
4. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, Varani K, Borea PA (2002b) 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2, 4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 45:115-126
5. Baraldi PG, Tabrizi MA, Fruttarolo F, Bovero A, Avitabile B, Preti D, Romagnoli R, Merighi S, Gessi S, Varani K, Borea PA (2003a) Recent developments in the field of A3 adenosine receptor antagonists. Drug Dev Res 58:315-329 (Pubitemid 36676331)
6. Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, Moorman A, Varani K, Gessi S, Merighi S, Borea PA (2003b) Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J Med Chem 46:1229-1241
7. Baraldi PG, Tabrizi MA, Preti D, Bovero A, Fruttarolo F, Romagnoli R, Zaid NA, Moorman AR, Varani K, Borea PA (2005a) New 2-arylpyrazolo[4,3-c] quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem 48:5001-5008
8. Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Romagnoli R, Zaid NA, Moorman AR, Merighi S, Varani K, Borea PA (2005b) New pyrrolo[2,1-f ]purine-2,4-dione and imidazo[2,1-f ]purine- 2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem 48:4697-4701 (Pubitemid 40993429)
9. Baraldi PG, Tabrizi MA, Romagnoli R, El-Kashef H, Preti D, Bovero A, Fruttarolo F, Gordaliza M, Borea PA (2006) Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidine template: organic and medicinal chemistry approach. Curr Org Chem 10:259-275
10. Bhattacharya P, Leonard JT, Roy K (2005) Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques. Bioorg Med Chem 13:1159-1165 (Pubitemid 40164600)
11. Biagi G, Bianucci AM, Coi A, Costa B, Fabbrini L, Giorgi I, Livi O, Micco I, Pacchini F, Santini E, Leonardi M, Nofal FA, Salernid OL, Scartonia V (2005) 2,9-Disubstituted-N6- (arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: synthesis, biochemical and molecular modelling studies. Bioorg Med Chem 13:4679-4693
12. Cacciari B, Bolcato C, Spalluto G, Klotz KN, Bacilieri M, Deflorian F, Moro S (2007) Pyrazolotriazolo- pyrimidines as adenosine receptor antagonists: a complete structure-activity profile. Purinergic Signal 3:183-193
13. Catarzi D, Colotta V, Varano F, Calabri FR, Lenzi O, Filacchioni G, Trincavelli L,Martini C, Tralli A, Christian M, Moro S (2005a) 2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists. Bioorg Med Chem 13:705-715
14. Catarzi D, Colotta V, Varano F, Lenzi O, Filacchioni G, Trincavelli L, Martini C, Montopoli C, Moro S (2005b) 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substitued derivatives. J Med Chem 48:7932-7945
15. Chang LC, von Frijtag Drabbe K̈unzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, IJzerman AP (2005) A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 48: 2045-2053
16. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (2000) Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo [3,4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem 43:3118-3124
17. Colotta V, Catarzi D, Varano F, Calabri FR, Lenzi O, Filacchioni G, Martini C, Trincavelli L, Deflorian F, Moro S (2004) 1,2,4-Triazolo[4,3-a] quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies. J Med Chem 47:3580-3590
18. Colotta V, Catarzi D, Varano F, Capelli F, Lenzi O, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Pugliese AM, Pedata F, Schiesaro A, Morizzo E, Moro S (2007) New 2-arylpyrazolo[3,4- c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 50:4061-4074
19. Cordeaux Y, Briddon SJ, Alexander SP, Kellam B, Hill SJ (2008) Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J 22:850-860
20. Costanzi S, Tikhonova IG, Harden TK, Jacobson KA (2008) Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des doi:10.1007/s10822-008- 9218-3
21. Cosyn L, Gao ZG, Van Rompaey P, Lu C, Jacobson KA, Van Calenbergh S (2006a) Synthesis of hypermodified adenosine derivatives as selective adenosine A3 receptor ligands. Bioorg Med Chem 14:1403-1412
22. Cosyn L, Palaniappan KK, Kim SK, Duong HT, Gao ZG, Jacobson KA, Van Calenbergh S (2006b) 2-Triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem 49:7373-7383
23. Da Settimo F, Primofiore G, Taliani S, Marini AM, La Motta C, Simorini F, Salerno S, Sergianni V, Tuccinardi T, Martinelli A, Cosimelli B, Greco G, Novellino E, Ciampi O, Trincavalle ML, Martini C (2007) 5-Amino-2-phenyl[1,2,3] triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists. J Med Chem 50:5676-5684
24. DeNinno MP, Masamune H, Chenard LK, DiRico KJ, Eller C, Etienne JB, Tickner JE, Kennedy SP, Knight DR, Kong J, Oleynek JJ, Tracey WR, Hill RJ (2003) 3--Aminoadenosine-5-- uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. J Med Chem 46:353-355
25. DeNinno MP, Masamune H, Chenard LK, DiRico KJ, Eller C, Etienne JB, Tickner JE, Kennedy SP, Knight DR, Kong J, Oleynek JJ, TraceyWR, Hill RJ (2006) The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor. Bioorg Med Chem Lett 16:2525-2527
26. Drabczýnska A, Schumacher B, M̈uller CE, Karolak-Wojciechowska J, Michalak B, Pȩkala E, Kiéc-Kononowicz K (2003) Impact of the aryl substituent kind and distance from pyrimido[2,1- f ]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur J Med Chem 38:397-402
27. Elzein E, Palle V, Wu Y, Maa T, Zeng D, Zablocki J (2004) 2-Pyrazolyl-N6-substituted adenosine derivatives as high affinity and selective adenosine A3 receptor agonists. J Med Chem 47: 4766-4773 (Pubitemid 39195566)
28. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
29. Gallo-Rodriguez C, Ji X-D, Melman N, Siegman BD, Sanders LH, Orlina J, Fischer B, Pu Q-L, Olah ME, van Galen PJM, Stiles GL, Jacobson KA (1994) Structure-activity relationships of N6-benzyladenosine-5-uronamides as A3-selective adenosine agonists. J Med Chem 37: 636-646 (Pubitemid 24102184)
30. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA (2002) Structural determinants of A3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem 45:4471-4484
31. Gao ZG, Blaustein J, Gross AS, Melman N, Jacobson KA (2003) N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol 65: 1675-1684
32. Gao ZG, Mamedova L, Chen P, Jacobson KA (2004) 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol 68: 1985-1993
33. Gao ZG, Kim SK, IJzerman AP, Jacobson KA (2005) Allosteric modulation of the adenosine family of receptor. Mini Rev Med Chem 5:545-553
34. Gao ZG, Joshi BV, Klutz A, Kim SK, Lee HW, Kim HO, Jeong LS, Jacobson KA (2006a) Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5-ribofuran-uronamide moiety. Bioorg Med Chem Lett 16:596-601
35. Gao ZG, Duong HT, Sonina T, Lim SK, Van Rompaey P, Van Calenbergh S, Mamedova L, Kim HO, Kim MJ, Kim AY, Liang BT, Jeong LS, Jacobson KA (2006b) Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J Med Chem 49:2689-2702
36. Gatta F, Del Giudice MR, Borioni A, Borea PA, Dionisotti S, Ongini E (1993) Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i] purines: new potent adenosine A2 receptor antagonists. Eur J Med Chem 28:569-576
37. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123-140
38. G̈oblÿos A, Gao ZG, Brussee J, Connestari R, Neves Santiago S, Ye K, IJzerman AP, Jacobson KA (2006) Structure-activity relationships of 1H-imidazo[4,5-c]quinolin-4-amine derivatives new as allosteric enhancers of the A3 adenosine receptor. J Med Chem 49:3354-3361
39. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264
40. Jacobson KA, Nikodijevic O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, Daly JW (1993) A role for central A3-adenosine receptors: mediation of behavioral depressant effects. FEBS Lett 336:57-60
41. Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, Meshulmam Y, Stiles GL, Kim HO (1995) Structure-activity relationships of 9-alkyladenine and ribose modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem 38:1720-1735
42. Jacobson KA, Park KS, Jiang J-L, Kim YC, Olah ME, Stiles GL, Ji X-D (1997) Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 36:1157-1165
43. Jacobson KA, Ji X-d, Li AH, Melman N, Siddiqui MA, Shin KJ, Marquez VE, Ravi RG (2000) Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem 43:2196-2203
44. Jacobson KA, Gao ZG, Chen A, Barak D, Kim SA, Lee K, Link A, Van Rompaey P, Van Calenbergh S, Liang BT (2001) Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem 44:4125-4136
45. Jacobson KA, Ohno M, Duong HT, Kim SK, Tchilibon S, Cesnek M, Holy A, Gao ZG (2005) A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. Chem Biol 12:237-247
46. Jeong LS, Lee HW, Jacobson KA, Kim HO, Shin DH, Lee JA, Gao ZG, Lu C, Duong HT, Gunaga P, Lee SK, Jin DZ, Chun MW, Moon HR (2006a) Structure-activity relationships of 2-chloro- N6-substituted-4-thioadenosine-5-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J Med Chem 49:273-281
47. Jeong LS, Lee HW, Kim HO, Jung JY, Gao ZG, Duong HT, Rao S, Jacobson KA, Shin DH, Lee JA, Gunaga P, Lee SK, Jin DZ, Chun MW (2006b) Design, synthesis, and biological activity of N6-substituted-4-thioadenosines at the human A3 adenosine receptor. Bioorg Med Chem 14:4718-4730
48. Jeong LS, Choe SA, Gunaga P, Kim HO, Lee HW, Lee SK, Tosh DK, Patel A, Palaniappan KK, Gao ZG, Jacobson KA, Moon HR (2007) Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4-thioadenosine derivatives without 4-hydroxymethyl group as highly potent and selective antagonists. J Med Chem 50:3159-3162
49. Jeong LS, Lee HW, Kim HO, Tosh D, Pal S, Choi WJ, Gao ZG, Patel AR, Williams W, Jacobson KA, Kim HD (2008) Structure-activity relationships of 2-chloro-N6-substituted- 4-thioadenosine-5-N,N-dialkyluronamides as human A3 adenosine receptor antagonists. Bioorg Med Chem 18:1612-1616
50. Ji Xd, Melman N, Jacobson KA (1996) Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 39:781-788
51. Jung K-Y, Kim S-K, Gao Z-G, Gross AS, Melman N, Jacobson KA, Kim YC (2004) Structure- activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. Bioorg Med Chem 12:613-623
52. Kim HO, Ji X-D, Siddiqi SM, Olah ME, Stiles GL, Jacobson KA (1994a) 2-Substitution of N6- benzyladenosine-5-uronamides enhances selectivity for A3-adenosine receptors. J Med Chem 37:3614-3621
53. Kim HO, Ji X-D, Melman N, Olah ME, Stiles GL, Jacobson KA (1994b) Selective ligands for rat A3-adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine-7-riboside derivatives. J Med Chem 37:4020-4030 (Pubitemid 24379691)
54. Kim YC, Ji X-D, Jacobson KA (1996) Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem 39:4142-4148
55. Kim SK, Gao Z-G, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, Jacobson KA (2003) Modeling the adenosine receptors: comparison of binding domains of A2A agonist and antagonist J Med Chem 46:4847-4859
56. Kim SK, Gao ZG, Jeong LS, Jacobson KA (2006) Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. J Mol Graph Model 25:562-577
57. Lee K, Ravi RG, Ji X-D, Marquez VE, Jacobson KA (2001) Ring-constrained (N)methanocarbanucleosides as adenosine receptor agonists: independent 5-uronamide and 2-deoxy modifications. Bioorg Med Chem Lett 11:1333-1337
58. Lenzi O, Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Varani K, Marighetti F, Morizzo E, Moro S (2006) 4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin- 1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 49:3916-3925
59. Li AH, Moro S, Melman N, Ji XD, Jacobson KA (1998) Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 41:3186-3201
60. Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, Cunha RA (2003) Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport 14:1645-1648
61. Maconi A, Pastorin G, Da Ros T, Spalluto G, Gao ZG, Jacobson KA, Baraldi PG, Cacciari B, Varani K, Moro S, Borea PA (2002) Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A3 adenosine receptor antagonist. J Med Chem 45:3579-3582 (Pubitemid 34856098)
62. Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, Matteucci MD (1996) Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides. J Med Chem 39:3739-3747
63. Matot I, Weininger CF, Zeira E Galun E, Joshi BV, Jacobson KA (2006) A3 Adenosine receptors and mitogen activated protein kinases in lung injury following in-vivo reperfusion. Crit Care 10:R65, doi:10.1186/cc4893 (Pubitemid 47079866)
64. Melman, A, Gao, ZG, Kumar, D, Wan, TC, Gizewski, E, Auchampach, JA, Jacobson, KA (2008a) Design of (N)-methanocarba adenosine 5--uronamides as species-independent A3 receptorselective agonists. Bioorg Med Chem Lett 18:2813-2819
65. Melman A, Wang B, Joshi BV, Gao ZG, de Castro S, Heller CL, Kim SK, Jeong LS, Jacobson KA (2008b) Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem 16:8546-8556
66. MeyerhofW,M̈uller-Brechlin R, Richter D (1991) Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 284:155-160
67. Moro S, Braiuca P, Deflorian F, Ferrari C, Pastorin G, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G (2005) Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine derivatives as a key study. J Med Chem 48:152-162
68. Moro S, Spalluto G, Gao ZG, Jacobson KA (2006) Progress in pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 26:131-159
69. M̈uller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, Daly JW (2002a) Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A2Aand A3-adenosine receptor antagonists. J Med Chem 45:3440-3450
70. M̈uller CE, Diekmann M, Thorand M, Ozola V (2002b) [3H]8-Ethyl-4-methyl-2-phenyl-(8R)- 4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin- 5-one ([3H]PSB-11), a novel high affinity antagonist radioligand for human A3 adenosine receptors. Bioorg Med Chem Lett 12:501-503
71. M̈uller CE (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 3:445-462
72. Novellino E, Barbara Cosimelli, Marina Ehlardo, Giovanni Greco, Manuela Iadanza, Antonio Lavecchia, Rimoli MG, Sala A, Da Settimo A, Primofiore G, Da Settimo F, Taliani S, La Motta C, Klotz KN, Tuscano D, Trincavelli ML, Martini C (2005) 2-(Benzimidazol-2- yl)quinoxalines: a novel class of selective antagonists at human A1 and A3 adenosine receptors designed by 3D database searching. J Med Chem 48:8253-8260
73. Ohana G, Bar-Yehuda S, Barer F, Fishman P (2001) Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol 186:19-23
74. Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Blaustein J, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA (2004) Modulation of adenosine receptor affinity and intrinsic efficacy in nucleosides substituted at the 2-position. Bioorg Med Chem 12: 2995-3007
75. Okamura K, Kurogi Y, Nishikawa H, Hashimoto K, Fujiwara H, Nagao Y (2002) 1,2,4- triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A3 receptor ligands. J Med Chem 45:3703-3708
76. Okamura T, Kurogi Y, Hashimoto K, Nagao Y (2004a) Facile synthesis of fused 1,2,4-triazolo[1,5- c]-pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett 14:2443-2446
77. Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, Nagao Y (2004b) Structureactivity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett 14:3775-3779
78. Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, M̈uller CE (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors. Bioorg Med Chem 11:347-356
79. Pastorin G, Da Ros T, Bolcato C, Montopoli C, Moro S, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G (2006) Synthesis and biological studies of a new series of 5 heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. J Med Chem 49:1720-1729
80. Perreira M, Jiang J, Klutz AM, Gao ZG, Shainberg A, Lu C, Thomas CJ, Jacobson KA (2005) Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 48:4910-4918
81. Press NJ, Keller TH, Tranter P, Beer D, Jones K, Faessler A, Heng R, Lewis C, Howe T, Gedeck P, Mazzoni L, Fozard JR (2004) New highly potent and selective adenosine A3 receptor antagonists. Curr Top Med Chem 4:863-870
82. Priego EM, von Frijtag Drabbe Kuenzel J, IJzerman AP, Camarasa MJ, Ṕerez-Ṕerez MJ (2002) Pyrido[2,1-f ]purine-2,4-dione derivatives as a novel class of highly potent human A3 adenosine receptor antagonists. J Med Chem 45:3337-3344
83. Pugliese AM, Coppi E, Volpini R, Cristalli G, Corradetti R, Jeong LS, Jacobson KA, Pedata F (2007) Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygenglucose deprivation episodes of different duration. Biochem Pharmacol 74:768-779
84. Saki M, Tsumuki H, Nonaka H, Shimada J, Ichimura M (2002) KF26777 (2-(4-bromophenyl)- 7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol 444:133-144
85. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson, RG (1993) Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci 90:10365-10369
86. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA (2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996
87. Shneyvais V, Mamedova L, Zinman T, Jacobson KA, Shainberg A (2001) Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 33:1249-1261
88. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist JA III, Schneller SW, Cristalli G, Stiles GL, Johnson Cr, IJzerman AP (1995) Search for new purineand ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem 38:1174-1188
89. Strickler J, Jacobson KA, Liang BT (1996) Direct preconditioning of cultured chick ventricular myocytes: novel functions of cardiac adenosine A2A and A3 receptors. J Clin Invest 98: 1773-1779
90. Tafi A, Bernardini C, Botta M, Corelli F, Andreini M, Martinelli A, Ortore G, Baraldi PG, Fruttarolo F, Borea PA, Tuccinardi T (2006) Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem 49:4085-4097
91. Tchilibon S, Kim SK, Gao ZG, Harris BA, Blaustein J, Gross AS,Melman N, Jacobson KA (2004) Exploring distal regions of the A3 adenosine receptor binding site: sterically-constrained N6- (2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem 12: 2021-2034
92. Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA (2005) (N)-Methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem 48:1745-1758
93. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR (2003) Novel N6-substituted adenosine 5--N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 285: H2780-H2787
94. van Galen PJM, van Bergen AH, Gallo-Rodriguez C, Melman N, Olah ME, IJzerman AP, Stiles GL, Jacobson KA (1994) A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol 45:1101-1111 (Pubitemid 24195566)
95. van Muijlwijk-Koezen JE, Timmerman H, Link R, von der Goot H, Menge WMPB, von Frijtag von Drabbe K̈unzel JK, de Groote M, IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptor. J Med Chem 43:2227-2238
96. van Muijlwijk-Koezen JE, Timmerman H, Vollinga RC, von Drabbe K̈unzel JF, de Groote M, Visser S, IJzerman AP (2001) Thiazole and thiazole analogues as novel class of adenosine receptor antagonists. J Med Chem 44:749-762
97. Van Rompaey P, Jacobson KA, Gross AS, Gao ZG, Van Calenbergh S (2005) Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. Bioorg Med Chem 13:973-983
98. van Tilburg EW, von Frijtag Drabbe Kunzel J, de Groote M, IJzerman AP (2002) 2, 5- Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A1, A2A, and A3 receptor. J Med Chem 45:420-429
99. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA (2000) [3H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol 57: 968-975
100. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2002) N6-Alkyl- 2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands. J Med Chem 45:3271-3279
101. Volpini R, Dal Ben D, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli GJ (2007) N6- Methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem 50:1222-1230
102. Yaar R, Lamperti ED, Toselli PA, Ravid K (2002) Activity of the A3 adenosine receptor gene promoter in transgenic mice: characterization of previously unidentified sites of expression. FEBS Lett 532:267-272
103. Yang H, Avila MY, Peterson-Yantorno K, Coca-Prados M, Stone RA, Jacobson KA, Civan MM (2005) The cross-species A3 adenosine-receptor antagonist MRS1292 inhibits adenosinetriggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res 30: 747-754
104. Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O (1992) Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci USA 89:7432-7436
105. Zhu R, Frazier CR, Linden J, Macdonald TL (2006) N6-Ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists. Bioorg Med Chem Lett 16:2416-2418